← Back to Search

CAR T-cell Therapy

CTX110 for B-Cell Cancers

Phase 1 & 2
Waitlist Available
Research Sponsored by CRISPR Therapeutics AG
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
For NHL patients: Age ≥18 years.
For B cell ALL patients: age ≥18 years to ≤70 years.
Must not have
Presence of bacterial, viral, or fungal infection that is uncontrolled or requires IV anti-infectives.
For NHL patients: prior allogeneic HSCT.
Screening 3 weeks
Treatment Varies
Follow Up from ctx110 infusion up to 60 months post-infusion
Awards & highlights


This trial is testing a new drug, CTX110, for safety and effectiveness in treating people with B-cell malignancies that have come back or are not responding to treatment.

Who is the study for?
This trial is for adults with B-cell malignancies like non-Hodgkin's lymphoma or acute lymphoblastic leukemia that didn't respond to at least two prior treatments. Participants must be in good physical condition, have well-functioning major organs, and not be pregnant or breastfeeding. They should agree to use contraception and join a follow-up study.Check my eligibility
What is being tested?
The CARBON trial is testing the safety and effectiveness of CTX110, a new therapy for people with certain blood cancers that have come back or haven't responded to treatment. It's an early-phase study where everyone gets the same experimental treatment.See study design
What are the potential side effects?
While specific side effects of CTX110 are not listed here, similar therapies can cause immune reactions, infections due to lowered immunity, fatigue, fever, and potential organ damage among other symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I am 18 years old or older with non-Hodgkin lymphoma.
I am between 18 and 70 years old with B cell ALL.
I am fully active or can carry out light work.
I am at least 18 years old.
My non-Hodgkin lymphoma or B cell ALL has not improved after at least 2 treatments.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
I do not have an ongoing serious infection requiring IV drugs.
I have had a stem cell transplant from a donor for my lymphoma.
I have not received gene or genetically modified cell therapies.
I do not have active HIV, hepatitis B, or hepatitis C.
My cancer has spread to my brain or spinal cord.
I have an immune system disorder or autoimmune disease and am on steroids or other immune-weakening medicines.
I have B cell ALL and had a bone marrow transplant within the last 6 months or have signs of graft-versus-host disease.
I have a history of seizures, stroke, dementia, cerebellar disease, or autoimmune disease affecting my brain.
I am not pregnant or breastfeeding.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from ctx110 infusion up to 60 months post-infusion
This trial's timeline: 3 weeks for screening, Varies for treatment, and from ctx110 infusion up to 60 months post-infusion for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Phase 1 Part A (Dose Escalation), for all cohorts: Incidence of adverse events, defined as dose-limiting toxicities
Phase 1 Part B (Cohort Expansion) and Phase 2: Objective response rate
Secondary outcome measures
Duration of Clinical Benefit (DOCB)
Duration of Response
Objective Response Rate (for B cell ALL)
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: CTX110Experimental Treatment1 Intervention
Administered by IV infusion following lymphodepleting chemotherapy.

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
CAR-T cell therapy, such as CTX110, involves modifying a patient's T cells to express a chimeric antigen receptor (CAR) that specifically targets the CD19 protein found on the surface of B cells. Once these engineered T cells are infused back into the patient, they can recognize and kill CD19-expressing cancer cells. This targeted approach is significant for B-Cell Cancer patients because it offers a personalized treatment option that can lead to durable remissions, especially in cases where traditional therapies have failed. The specificity of CAR-T cells for CD19 helps to minimize damage to healthy cells, potentially reducing side effects compared to conventional chemotherapy.

Find a Location

Who is running the clinical trial?

CRISPR Therapeutics AGLead Sponsor
8 Previous Clinical Trials
665 Total Patients Enrolled
Sarah Cohen, MDStudy DirectorCRISPR Therapeutics
2 Previous Clinical Trials
146 Total Patients Enrolled
Ewelina Morawa, MDStudy DirectorCRISPR Therapeutics
1 Previous Clinical Trials
26 Total Patients Enrolled

Media Library

CTX110 (CAR T-cell Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04035434 — Phase 1 & 2
B-Cell Cancers Research Study Groups: CTX110
B-Cell Cancers Clinical Trial 2023: CTX110 Highlights & Side Effects. Trial Name: NCT04035434 — Phase 1 & 2
CTX110 (CAR T-cell Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04035434 — Phase 1 & 2
~63 spots leftby Jul 2026